Can a vaccine cocktail free HIV patients from daily pills?
NCT ID NCT04357821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether a combination of two experimental vaccines, an immune booster, and two powerful antibodies can help people with HIV control the virus after stopping their daily antiretroviral therapy. Eleven participants will receive the regimen while on ART, then pause their regular medication to see if the virus stays at bay. The goal is to achieve a lasting remission, not a cure, as the virus may still be present but kept under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination of DNA vaccine, MVA vaccine, TLR9 agonist (lefitolimod), and broadly neutralizing antibodies (VRC07-523LS and 10-1074)
- What this could lead to
- If it works, this could point toward a way for people with HIV to stop daily antiretroviral therapy and keep the virus under control for months or longer.
- What could go wrong
- This is a very small, early-phase study with only 11 participants, so results may not apply widely. The combination is complex and could cause side effects, and there is no guarantee of achieving remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zuckerberg San Francisco General Hospital, University of California San Francisco
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a robot help stroke survivors with HIV walk again?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- Can a Father-Focused program curb HIV, substance abuse, and violence?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test